To investigate the effectiveness of a novel isoquinoline derivative, EDL-155, in killing retinoblastoma in vitro and in vivo. METHODS. Dose-response curves were generated in which Y79 retinoblastoma cells tagged with luciferase (Y79-Luc) were treated with serial concentrations of EDL-155. Electron microscopy was used to evaluate the ultrastructural morphology of EDL-155-treated Y79 cells. To determine whether autophagy was induced in EDL-155-treated Y79-Luc cells, staining with acridine orange and LC-3 immunoblot analysis was performed. To evaluate the efficacy of EDL-155 in vivo, Y79-Luc retinoblastoma cells were injected into the vitreous cavity of newborn rats, followed by periocular injections of EDL-155 (20 mg/kg/ day) or an equivalent dosage of saline. RESULTS. EDL-155 appeared to destroy the retinoblastoma cells in vitro with an EC 50 of 9.1 M. EDL-155-treated retinoblastoma cells displayed a lack of viable mitochondria and the presence of autophagosomes wrapped in the characteristic double membranes. Acridine orange staining of EDL-155-treated retinoblastoma cells demonstrated the accumulation of vacuoles, and the immunoblots displayed a shift in molecular weight of LC-3, indicative of incorporation into autophagosome vesicles. In the retinoblastoma animal model, four doses of EDL-155 were delivered over 4 days, which was sufficient to see a significant decrease (P ϭ 0.01) in viable intraocular tumors. Seven of the 25 rats treated with EDL-155 had no detectable living tumor. No significant decrease in viable tumor was observed in control animals. CONCLUSIONS. EDL-155 appears to eliminate retinoblastoma cells by disrupting mitochondria and inducing autophagy. Local delivery of EDL-155 may be an effective therapy for some types of ocular cancers. (Invest Ophthalmol Vis Sci. 2010;51: 3813-3819)
R etinoblastoma accounts for approximately 12% of all cancers in children younger than 1 year of age worldwide. Retinoblastoma is diagnosed in approximately 5000 children each year, and approximately 300 cases occur in the United States. [1] [2] [3] [4] Ninety-five percent of the cases are diagnosed in children within the first 3 years of life. 4 In the United States, the cure rate for retinoblastoma is greater than 90%. In 3 of 4 cases, retinoblastoma occurs unilaterally. Children with unilateral retinoblastoma generally undergo surgical enucleation, whereas the current standard of care for bilateral cases includes a combination of chemotherapy and focal therapies. 5 These focal therapies may include, but are not limited to, cryotherapy, laser therapy, and radiation therapy. 5 Each type of treatment can be used alone or in combination with one or more of the other therapies. Traditional therapies, such as external beam radiation, are associated with a high incidence of secondary cancers (e.g., bone, nasal cavity, brain) and a high incidence of morbidity (e.g., cataracts, optic nerve damage). 6, 7 For these reasons, current treatments are aimed at avoiding these aggressive approaches.
The best approach for the preservation of the eye and visual sparing is combination therapy. Well-known protocols include the use of both vincristine and carboplatin 2, 3, 8, 9 in combination with carboplatin and etoposide 10 or vincristine, carboplatin, and etoposide. [11] [12] [13] [14] [15] Although generally well tolerated, these regimens produce side effects that include myelosuppression and toxicity. In addition, some tumors are resistant to current approaches.
Our laboratory is involved in the discovery and development of novel agents to treat CNS tumors. Previous studies within our laboratory have examined a tetrahydroisoquinoline derivative (1-(biphenyl-4-ylmethyl)-1,2,3,4-tetrahydroisoquinoline-6,7-diol), EDL-155, (Fig. 1A) and its ability to kill glioblastoma in vitro and in vivo. 16, 17 In these studies, EDL-155 was selectively cytotoxic against C6 rat glioblastoma cells with an EC 50 of 1.5 M compared with primary cultured rat neonatal astrocytes, which had an EC 50 of 15.3 M.
17 When EDL-155 was pumped directly into the brains of animals in which C6 gliomas had been implanted, the tumor size was significantly reduced. 16, 17 EDL-155 was effective in selectively killing glioblastoma; however, pharmacokinetic studies revealed that 90% of EDL-155 was metabolized by catechol-O-methyltransferase after a single pass through the liver, which presents a major problem in using EDL-155 as a treatment for glioblastoma. 18 This rapid metabolism may be beneficial for treating local cancers because any drug entering the vascular supply would be rapidly metabolized in the liver. Pharmacokinetic studies within our laboratory reveal that after periocular delivery of EDL-155 in rats, the concentration in the vitreous is sevenfold higher than the concentration in the plasma. The terminal half-life of EDL-155 in the vitreous and plasma was approximately 13 minutes. 19 In light of these pharmacokinetics studies, we chose to test EDL-155 on an ocular cancer, retinoblastoma.
MATERIALS AND METHODS

Luciferase Assay
Human Y79 retinoblastoma cells carrying the luciferase reporter gene (Y79-Luc) were a generous gift from Michael Dyer at St. Jude Children's Research Hospital (Memphis, TN). The Y79-Luc cells were maintained in basal medium Eagle (BME; Mediatech, Herndon, VA) supplemented with 10% fetal calf serum (HyClone, Logan, UT). The cells were plated at a density of 10 3 cells/well in a 96-well plate and were cultured in a 37°C incubator containing a humid 5% CO 2 atmosphere. Before treatment, the 10% FCS BME was replaced with 2% FCS BME containing either vehicle (dimethyl sulfoxide [DMSO] in normal saline) or serial concentrations of EDL-155 (0.001-100 M). EDL-155 was synthesized in the laboratory of one of the authors (DDM). Dilutions of EDL-155 were made so that the DMSO concentrations remained at 0.01% (vol/vol). The Y79-Luc cells were incubated for 24, 48, and 96 hours. Luciferin (150 g/mL) was added to the culture medium, and luminescence was monitored on a microplate reader spectrophotometer (FLx800; Quant; BioTek, Winooski, VT).
Electron Microscopy
A human retinoblastoma cell line, Y79 (ATCC, Manassas, VA), was maintained as described. Y79 cells were treated with EDL-155 (5 M) for 19 hours before fixation. Cultured Y79 cells were fixed with 2% paraformaldehyde and 2% glutaraldehyde in PBS (pH 7.3). The cells were centrifuged and postfixed in 1% osmium tetroxide for 1 hour at room temperature. Next, the Y79 cells were rinsed in PBS, dehydrated, and infiltrated with Spurr embedding medium. Silver to gold sections were cut on a microtome (Ultracut E; Histostat; Reichert, Morris Plains, NJ), and the sections were examined under an electron microscope (2000EX; JEOL Tokyo, Japan).
LC-3 Immunoblotting
Y79-Luc cells were treated with EDL-155 (0, 5, 20 M) for 4 and 48 hours. After treatment, the cell lysates were run on an SDS-PAGE gel (8%-20%), and proteins were transferred to a nitrocellulose membrane and probed for Ponceau to ensure equal protein loading (data not shown). LC-3 antibody (Cell Signaling, Danvers, MA) was used at 1:1000 dilution, followed by the secondary antibody, peroxidase conjugated donkey anti-rabbit, at 1:1000 dilution. LC-3 was detected with an enhanced chemiluminescence detection kit (Thermo Scientific Pierce, Rockford, IL) and a digital imaging system (Image Station 4000 MM; Kodak, Rochester, NY).
Detection of Autophagic Vacuoles
Y79-Luc tumor cells were treated with EDL-155 (0, 5, 20 M) for 4 and 48 hours. The cells were stained with 1 g/mL acridine orange (Molecular Probes-Invitrogen, Carlsbad, CA) for 15 minutes, washed with media, and examined under a confocal microscope (Nikon, Tokyo, Japan) at 60ϫ objective lens magnification.
In Vivo Y79-Luc Model
Y79-Luc cells (100,000) were suspended in Hank's buffered salt solution and injected into the right eye of 60 Sprague-Dawley rat pups within 24 hours of birth (day 0). On day 10, luciferin (150 mg/kg body weight; Xenogen, Cranbury, NJ) was injected into the peritoneal cavity of each rat, and 30 minutes later the animals were scanned using a digital imaging system (Image Station 4000 MM; Kodak). Of the 60 pups injected with Y79-Luc cells, 35 displayed luminescence in the eye. The animals that presented luciferase-positive eyes were randomly assigned to receive EDL-155 (n ϭ 25) or control vehicle (n ϭ 10). Rats in the treatment group received daily periocular injections of EDL-155 (20 mg/kg; 0.01% DMSO in normal saline) for 4 days. To monitor tumor viability, the animals were scanned on day 1 (before treatment), day 3 (after two treatments), and day 5 (after four treatments). Data were normalized to the initial luminescence coming from eyes on day 1, setting the luminescence units to 100 and monitoring all subsequent changes relative to this starting value. The statistical significance of the difference between the means was determined using the one-tailed Student's t-test.
Histology
The rats were anesthetized with 13 mg/kg rompum and 87 mg/kg ketalar perfused through the heart (with saline), followed by 4% paraformaldehyde in PBS (pH 7.3). Both eyes were removed and embedded in plastic and were sectioned at a thickness of 1 m and stained with toluidine blue. All experimental animals were used in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.
RESULTS
Effects of EDL-155 on Y79 Cells In Vitro
To test the efficacy of an isoquinoline derivative, EDL-155, (Fig.  1A ) on retinoblastoma cells, dose-response curves were generated (Figs. 1B-D). Y79-Luc cells were treated with serial dilutions of EDL-155 (0.001-100 M) for 24, 48, and 96 hours. Luminescence intensity was quantified, which enabled us to monitor the viability of the Y79-Luc retinoblastoma cells by directly observing the effects of the treatment over time. Twenty-four hours after treatment, we observed a decrease in luminescence intensity from the Y79-Luc cells, and the EC 50 of EDL-155 was 36.2 M (Fig. 1B) . The data also demonstrated that the luminescence and EC 50 concentrations continued to decrease over time with an EC 50 of 27.3 M after 48 hours (Fig.  1C ) and an EC 50 of 9.1 M at 96 hours (Fig. 1D ). These results suggest that theY79-Luc cells are relatively sensitive to the cytotoxic effects of EDL-155. A gradual decrease in luminescence over time was observed in these studies, which suggests a decline in adenosine triphosphate production that may be the result of a lack of normal mitochondria function in the EDL-155-treated Y79-Luc cells.
Ultrastructural Changes with EDL-155 Treatment
To evaluate the ultrastructural effects of EDL-155 on mitochondria and the general morphology of the retinoblastoma cells, Y79 cells were incubated with EDL-155 (5 M) for 19 hours. When the morphology of the retinoblastoma cells was evaluated, the control cells appeared to be normal Y79 cells with intact mitochondria and normal nuclear morphology (Figs. 2A,  2B ). In contrast, the Y79 cells treated with EDL-155 displayed distinct differences in the morphology that could be observed even at low magnification (Figs. 2C, 2D ). The most prominent features and morphologic differences in the EDL-155-treated tumor cells was the presence of many large vacuoles throughout the cytoplasm and the appearance of severely disrupted mitochondria. When examined at high magnification, the EDL-155-treated Y79 cells appeared to have organelles with double membranes, unlike the control cells (Figs. 2C, 2D ). The doublelayered organelles appeared to be autophagosomes, a hallmark of autophagy (programmed cell death type 2). 20 -22 Similar to the control cells, the EDL-155-treated cells displayed relatively normal nuclear morphology. Evidence to support nuclear fragmentation or condensation, hallmarks of apoptosis (programmed cell death type 1), 20 -22 was not observed. These ultrastructural findings provide important implications when analyzing the mechanistic action of EDL-155 in retinoblastoma cells. Although EDL-155 appears to disrupt the mitochondria in retinoblastoma cells, the morphologic hallmarks observed do not appear related to apoptosis. Instead the results show that EDL-155 induces autophagy in retinoblastoma cells.
Induction of Autophagy in EDL-155-Treated Y79 Cells
The ultrastructural changes observed in the EDL-155-treated retinoblastoma cells led us to examine the potential role of autophagy. One of the hallmarks of autophagy is a shift in the molecular weight of microtubule-associated protein 1 lightchain 3 (LC-3). 23 LC-3 is critical for amino acid starvationinduced autophagy and is associated with the autophagosome membrane. 23 If autophagy occurs within the retinoblastoma cells, there should be a characteristic shift in the molecular weight of LC-3 and, thus, the formation of autophagosomes.
To determine whether EDL-155 induced autophagy in retinoblastoma cells, Y79-Luc cells were treated with EDL-155 (0, 5, 20 M) for 4 and 48 hours and were probed for LC-3. As shown in Figure 3 , probing with LC-3 demonstrated a characteristic shift in molecular weight of LC-3, from LC-3 I to LC-3 II. The shift in molecular weight of LC-3 indicates that the cells treated with EDL-155 were undergoing autophagy.
To verify that autophagy was induced in the EDL-155-treated retinoblastoma cells, Y79 cells were stained with acridine orange. Acridine orange stains the cytoplasm and nucleolus bright green, whereas the acidic compartments (autophagosomes) fluoresce bright red or orange. 24, 25 In Figure 
Effect of EDL-155 In Vivo
To test the effectiveness of EDL-155 as an in vivo therapy, we used an animal model in which human retinoblastoma cells, Y79-Luc, were injected into the eyes of newborn rats. The luciferase tagged cells allowed us to monitor the growth of the intraocular tumor by imaging luminescence from the eye.
Representative scans from a control animal and an EDL-155-treated animal are shown in Figure 5 . Intraocular luminescence from the control rat increased from day 1 to day 3 (Figs. 5A, 5B) and remained elevated at day 5 ( Fig. 5C ), indicating that there was an increase in the intraocular tumor size. In the EDL-155-treated animal, little change in intraocular luminescence was observed after two doses (day 3 scan; Fig. 5E ). However, after four doses (day 5 scan; Fig. 5F ), there was a significant decrease in intraocular luminescence. Of the 25 rats treated with EDL-155, 23 had less luminescence coming from the tumor-bearing eye after four treatments than was present before treatment. Furthermore, seven of the 25 treated animals had no detectable intraocular luminescence after four doses of EDL-155.
These results were quantified and are presented in Figure 6 . The changes occurring in luminescence within the animals were standardized, as described in Materials and Methods. On day 1, both groups had a relative value of 100 with no error bars. Because each animal was set to a value of 100, there was no variability at this point. On day 3, the relative amount of luminescence increased in both groups. There was, on average, less luminescence from the treated group, but at this early time point this difference was not significant. By day 5, there was a dramatic and significant difference between the treated 1 (A, D), day 3 (B, E) , and day 5 (C, F) after treatment was initiated. In the control rats (A-C), a strong luminescence signal was observed on all days, indicating that the tumor was not adversely affected by the carrier solution. In the experimental rats (D-F), there was a decrease in ocular luminescence by day 5 (F), indicating the death of retinoblastoma cells.
and control groups. The mean luminescence of the control group appeared to decrease; however, there was not a significant difference from that observed on day 3. In the EDL-155-treated group, there was a significant decrease in luminescence. The mean luminescence of the EDL-155-treated group was significantly decreased on day 5 compared with day 3. Furthermore, there was a significant decrease relative to the values seen in the control group. Because of the rapid growth of the tumors in the control animals, the in vivo experiments were terminated on day 5. These data establish that EDL-155 caused a significant reduction in luminescence from the transplanted Y79 cells, and the data suggest a reduction in intraocular tumor size.
The animals appeared to tolerate the EDL-155 treatment. There was no significant difference in weight gain between treated animals and control animals. The control animals gained an average of 5.4 g over the treatment period, whereas treated animals gained an average of 4.6 g. These amounts represent a 24.2% weight gain for the control group and a 23.6% weight gain for the treated group. No differences were observed in the animals' motor skills or general appearance. In addition, we did not observe any local inflammation around the eyes of the EDL-155-treated animals compared with the eyes of the control animals.
To confirm that the intraocular tumor was affected by EDL-155 treatment, we examined the morphology of the tumor within the eye. Histologic sections demonstrated that the number of viable tumor cells was approximately equal to the luminescence observed at day 5 (Fig. 7) . In the control animals, there was a considerable amount of tumor within the vitreous chamber, and in some cases the tumor was invading the retina (Fig. 7A) . Occasionally, the tumor cells were observed invading the anterior and posterior chambers and penetrating the lens. When there was no luminescence, the Y79-Luc cells appeared to be dead (Fig. 7B) . Many of the nonviable Y79-Luc cells were filled with large vacuoles or were in an advanced state of degradation. Thus, the morphology of the intraocular tumor treated with EDL-155 indicates that EDL-155 killed the retinoblastoma cells.
DISCUSSION
To study the effects of EDL-155 in vivo, we chose a retinoblastoma rat model developed by Michael Dyer's group. The model is well characterized and very useful for short-term studies. 26 -28 Although this model doses not perfectly recapitulate human retinoblastoma, it does allow us to directly test the effectiveness of treating transplanted retinoblastoma with EDL-155. The rat pups began receiving EDL-155 treatment in the second week of life, before the blood-retinal barrier was fully developed. In humans, the average age of detection is 18 months, 4 well after the blood-retinal barrier is formed. Thus, in this model, EDL-155 would have greater access to tumor cells than would be expected in humans. Furthermore, the rat has a very small eye compared with the human eye, and the concentration of drug within the limited space of the rat vitreous may be considerably higher than in the human. 19 In human eyes, the difference in pharmacokinetics may make delivery of the drug difficult, and the intraocular drug concentration may not be sufficient at the site of tumors.
The results of the retinoblastoma animal model indicated a significant decrease in the luminescence emitted from the eyes of the EDL-155-treated animals compared with that emitted from control animals. Of the 25 animals given EDL-155 treat-FIGURE 6. Data from the control pups (n ϭ 10) and those treated with EDL-155 (n ϭ 25) are shown in normalized luminescence. The luminescence intensity of each rat was normalized to an arbitrary value of 100 on day 1. The change in luminescence was calculated for each rat, and the populations were plotted for scans performed 24 hours after two treatments (day 3) and four treatments (day 5) with EDL-155. Error bars represent the SEM. There was a statistically significant difference (P ϭ 0.01) between control and treated animals on day 5. ment, seven had no luminescence after four treatments over 4 days. This was not observed in the animals treated with vehicle alone. This retinoblastoma model provided information that may prove beneficial in treating human retinoblastoma or other ocular cancers.
In previous studies, 16, 17 we found that EDL-155 appeared to kill cultured glioma by sending the cells into autophagy. Similar to the EDL-155-treated glioma, the EDL-155-treated retinoblastoma displayed large vacuoles in the cytoplasm, and the nuclei appeared to be intact. When we examined the cells treated with EDL-155 at the electron microscopic level, normal mitochondria were absent while organelles wrapped in double membranes (autophagosomes) were present. These changes were not observed when we examined primary cultures of astrocytes treated with EDL-155. 16 The lack of nuclear condensation or fragmentation indicated that the cells did not die by apoptosis. In addition, cytoplasmic DNA laddering was absent in cells treated with EDL-155 (unpublished observation, 2005). All these observations indicate that autophagy may be a potential mechanism of action of EDL-155. It is important to note that these results do not completely eliminate the possibility that apoptosis is not involved at some point; however, as discussed, results do conclude that autophagy is induced in retinoblastoma cells treated with EDL-155.
Support of autophagy as the mechanism of cell death comes from the presence of double membranes surrounding many of the vacuoles in the EDL-155-treated cells. These double membranes are a hallmark of autophagy. 29 To provide additional evidence of autophagy as a mechanism of action, we examined two techniques to identify autophagy, LC-3 immunoblots and acridine orange staining. When cells enter autophagy, acidic autophagosomes are formed. In this process, LC-3 is modified, enters the autophagosomes, and undergoes a characteristic shift in molecular weight. In the present study, we observed a shift in LC-3 molecular weight only when cells were treated with EDL-155, providing further support that the cells were entering autophagy. The final evidence of autophagy comes from cells stained with acridine orange, which highlights newly formed acidic autophagosomes. We observed the red/orange staining of small organelles when the retinoblastoma cells were treated with EDL-155. Collectively, these data indicates that autophagy is a potential mechanism of action of EDL-155.
Autophagy has been implicated in cancer initiation and progression. Work is still being conducted to define the functional role of autophagy in cancer. Many treatments have the ability to induce autophagy (for a review see Ref. 30 48 and the sphingolipid ceramide. 49, 50 Several studies have identified small molecules that induce autophagy in PC3 prostate cancer 51 or in renal cell carcinoma. 52 In the present study, we have demonstrated that EDL-155 induces autophagy in retinoblastoma cell lines. We are examining the molecular interactions of EDL-155 in vitro to define the precise mechanism of action and the molecular target of EDL-155.
The potential benefits of using EDL-155 to treat local cancers are its rapid clearance (342.5 Ϯ 49.9 L/min/kg) and high volume of distribution (13,005 Ϯ 1187 L/kg). 18 After intravenous administration, EDL-155 undergoes extensive metabolism in the liver by cytochrome P-450 and in peripheral tissues by catechol-O-methyltransferase. Periocular administration increases the availability of the compound to the eye while decreasing systemic toxicity from hepatic metabolism. Thus, the potentially confounding problem of liver metabolism may actually be beneficial because of the decrease in systemic toxicity. We have tested only one concentration of EDL-155 (20 mg/kg).
In our animal model, EDL-155 is an effective treatment for retinoblastoma. Our data clearly indicate that this monotherapy is capable of producing significant tumor reduction. Most clinical protocols and preclinical research studies in animal models of retinoblastoma have used combinations of drugs. For example, one therapy uses topotecan with carboplatin of retinoblastoma (transgenic and xenograft), which has been shown to be superior to the combination of vincristine, carboplatin, and etoposide. 53 Recently, nutlin-3, an inhibitor of MDM2-p53 interaction in cells, was proposed for use in treating retinoblastoma. It was shown to be effective when used in combination with topotecan in a murine model of retinoblastoma. 54 Each of these compounds is associated with toxic side effects. Our initial studies have shown that EDL-155, used alone, provides a relatively effective therapy with no observable toxic side effects. Obviously the use of EDL-155 in combination with other chemotherapeutic agents may prove to be a more effective treatment, and future studies will examine the potential synergistic interactions of EDL-155.
